Because his life keeps moving, Novoeight® is designed to fit into his world

When starting patients on treatment, Novoeight® has much to offer:

David living with hemophilia A packing his car


David, 22 years old, lives with hemophilia A.


 



 

Novoeight Medicine Package


Each vial comes with a syringe appropriately pre-filled with diluent.

Learn how Novoeight® may be right for your patient

Find out how Novoeight® may help your patients who need treatment for hemophilia A.


 



 

Novoeight resources

Support for you

Find resources to help you learn about and counsel patients on Novoeight®.

The Novoeight satisfaction guarantee.

Terms and conditions apply.

Novoeight® Satisfaction Guarantee

Novo Nordisk is so confident in Novoeight® that we guarantee your patient’s satisfaction. 


References: 1. Novoeight® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2014. 2. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349-359. 3. Data on file, at Novo Nordisk Inc.; Plainsboro, NJ. Nov 2012.


 



 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.